Multiple sclerosis drugs will stay on the PBS - for now, but there's still a way to go
17 July 2026 ABC News
With the Minister announcing the intravenous MS medicines would remain on the PBS the immediate delisting battle may have been won but the war is still going with the PBAC announcing another review of the medicines. Without a legislated priority on patients - this is just the tip of the iceberg.
BAA Chair, Felicity McNeill PSM, discusses MS decision with Kate Richardson on ABC TV News. Watch here.
Multiple Sclerosis drugs saved from PBS pricing axe
16 July 2026 The Australian
The PBAC has written to the Minister for Health and Agreed to keep two intravenous MS medicines on the PBS at their current pricing - but with a catch.
BAA Chair, Felicity McNeill PSM, comments in an article by Natasha Robison. Read here.
PBS processes put procurement outcomes ahead of multiple sclerosis patients
14 July 2026 7:30 Report, ABC
It is putting patient access to medicines they have come to rely on at risk. Intravenous MS treatments are the latest example of this crisis in access, and its time for the government to change its approach and put patients before procurement.
BAA Chair, Felicity McNeill PSM, discusses PBS process with Nicole Hegarty on ABC 7:30 Report. Watch here.
Drug price disputes swamp advisory committee
8 July 2026 The Australian
With 10 appications for review of listing prices, price cuts, risk share arrangements the system is slowly suffering the death of a thousand cuts. The PBS has hit a tipping point and its time for the Government to take step back and put patients first in its consideration of medicine access on the PBS.
BAA Chair, Felicity McNeill PSM, comments in an article by Natasha Robison. Read here.
'An afterthought': Patients left waiting in drug price war
21 June 2026 The Australian
With 10 applications for review of listing prices, price cuts, risk share arrangements the system is slowly suffering the death of a thousand cuts. The PBS has hit a tipping point and its time for the Government to take step back and put patients first in its consideration of medicine access on the PBS.
BAA Chair, Felicity McNeill PSM, comments in an article by Natasha Robison. Read here.
Lifesaving drugs blocked by Australia's 'broken' approvals process
12 February 2026 The Australian
BAA highlighted that between overzealous price gauging by the Government and over ambitious price requests from industry, patients are missing out in a system of two adversaries trying to out bluff each other. Meanwhile, the hidden secret of Government listing items on the PBS and expecting companies to pay for those listings instead of the Government (risk share agreements) is a ticking time bomb of access being lost to existing listings and new listings never arriving.
BAA Chair, Felicity McNeill PSM, comments in an article by Natasha Robison. Read here.
BAA 2026-27 Budget Submission
Better Access Australia has released its 2026–27 Federal Budget priorities, calling for targeted reforms to improve healthcare affordability, expand access to life-saving medicines, deliver on the Government's newborn screening commitments, and introduce fairer means testing across major subsidy programs. The proposals aim to strengthen Australia's health system, improve equity, and ensure public funding is directed to those who need it most while delivering better outcomes for patients and taxpayers.
